Skip to search formSkip to main contentSkip to account menu

K 351

Known as: K-351 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1987
1987
Summary: Effect of 3–4-dihydro-8-(2-hydroxy-3-isopropylaminopropoxy)- 3-nitroxy-2H-1 -benzopyran (K-351) infused into the renal… 
1986
1986
The pharmacodynamic and pharmacological effects of nipradilol (K-351) were studied in a cross-over double blind fashion with… 
1985
1985
The pharmacokinetic parameters of nipradilol (NIP), a new potent antihypertensive and antianginal agent, and propranolol were… 
1985
1985
Binding characteristics of the β-antagonists and agonists with the β-adrenoceptors were investigated in [3H] dihydroalprenolol… 
1985
1985
Effects of nipradilol (K-351) on cardiac performance and myocardial oxygen consumption were investigated in anesthetized open… 
1985
1985
Summary: Effects of nipradilol (K-351), a newly developed antihypertensive agent, on electrophysiological properties of the heart… 
1985
1985
The metabolism and disposition of a new antihypertensive and antianginal agent, 3,4-dihydro-8-(2-hydroxy-3-isopropylamino)propoxy… 
1985
1985
After oral administration of [14C]-labelled 3,4-dihydro-8-(2-hydroxy-3-isopropylamino)propoxy-3-nitroxy-2H-1-b enzopyran… 
1984
1984
Effects of K-351 (3,4-dihydro-8-(2-hydroxy-3-isopropyl-aminopropoxy)-3-nitroxy++ +-2H-1-benzopyran) on hemodynamics and renin… 
1983
1983
Effects of beta-blockers on the blood pressure (BP), urinary output (V) and excretion of Na% (UNaV) and K+ (UKV) were studied in…